Acura Pharmaceuticals Inc. (NASDAQ:ACUR)

CAPS Rating: 3 out of 5

A pharmaceutical company engaged in research, development and manufacture of innovative Aversion(r) Technology and related product candidates.


Player Avatar zzlangerhans (99.85) Submitted: 10/2/2011 9:34:16 PM : Underperform Start Price: $3.27 ACUR Score: +16.61

Acura is up 15% today apparently because they were awarded a patent. Patents are a fairly common thing in biotech and small pharma, and in fact are a prerequisite for any attempt at commercialization of a product. So I'm not really surprised or impressed that Acura obtained a patent. What would impress me is if Acura is actually able to sell enough Oxecta or Impede PSE to justify their development costs. For reasons I've outlined in detail previously, I don't think they will. The dominant providers of opiate pain medications have no incentive to prescribe abuse-resistant products, barring legislation which has not even been proposed.

Featured Broker Partners